- Home
- LGL vs NRXP Comparison
LGL vs NRXP Comparison
Compare LGL & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGL
- NRXP
- Stock Information
- Founded
- LGL 1917
- NRXP 2015
- Country
- LGL United States
- NRXP United States
- Employees
- LGL N/A
- NRXP N/A
- Industry
- LGL Industrial Machinery/Components
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- LGL Technology
- NRXP Health Care
- Exchange
- LGL Nasdaq
- NRXP Nasdaq
- Market Cap
- LGL 38.5M
- NRXP 32.6M
- IPO Year
- LGL N/A
- NRXP N/A
- Fundamental
- Price
- LGL $7.51
- NRXP $3.00
- Analyst Decision
- LGL
- NRXP Strong Buy
- Analyst Count
- LGL 0
- NRXP 4
- Target Price
- LGL N/A
- NRXP $28.50
- AVG Volume (30 Days)
- LGL 13.7K
- NRXP 155.3K
- Earning Date
- LGL 08-12-2025
- NRXP 08-13-2025
- Dividend Yield
- LGL N/A
- NRXP N/A
- EPS Growth
- LGL 204.51
- NRXP N/A
- EPS
- LGL 0.08
- NRXP N/A
- Revenue
- LGL $4,322,000.00
- NRXP N/A
- Revenue This Year
- LGL N/A
- NRXP N/A
- Revenue Next Year
- LGL N/A
- NRXP N/A
- P/E Ratio
- LGL $99.26
- NRXP N/A
- Revenue Growth
- LGL 20.66
- NRXP N/A
- 52 Week Low
- LGL $5.03
- NRXP $1.10
- 52 Week High
- LGL $9.74
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- LGL 54.93
- NRXP 44.19
- Support Level
- LGL $7.52
- NRXP $2.89
- Resistance Level
- LGL $7.77
- NRXP $3.15
- Average True Range (ATR)
- LGL 0.19
- NRXP 0.14
- MACD
- LGL -0.02
- NRXP -0.04
- Stochastic Oscillator
- LGL 53.33
- NRXP 18.97
About LGL LGL Group Inc. (The)
LGL Group Inc is a holding company engaged in services, merchant investment and manufacturing business activities. The company has two reportable segments; Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.